The company is under investigation for alleged securities law violations, including issuing false/misleading statements and failing to disclose material information to investors, which indicates serious compliance and governance concerns.
The company achieved multiple significant operational milestones including completion of GMP pilot batch, successful dose-range finding toxicology studies with no adverse findings, expanded IP portfolio, and maintained funding runway. These accomplishments represent meaningful progress toward IND submission and clinical development, demonstrating execution on key development objectives.
Articles that tag CURX but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
